β2M is a well-recognized prognostic biomarker in various B-cell malignancies, including DLBCL, HL, FL, MM, and CLL, and it is even recommended by the International Staging System for stratifying MM patients (10–18). Here, B2M is linked to B-cell chronic lymphocytic leukemia.